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Summary Urinary gonadotrophin peptide (UGP) was originally identified by immunoassay in the urine of
patients with various types of cancer and by immunohistochemistry in human cancers of various histological
types. Extracts of normal adult male urine also contained UGP by immunoassay. Purified UGP from different
starting material was subjected to high pressure liquid chromatography (HPLC) prior to defining amino acid
sequences. Chromatographed UGP after HPLC showed three distinct fractions. The N-terminal sequence of
peptide 2 was completely homologous with the beta-core fragment of human chorionic gonadotrophin (hCG)
and this was found associated with two smaller peptides. The N-terminal sequence of peptide has not been
described previously whilst the N-terminus of peptide 3 that was sequenced showed complete homology with
the N-terminal sequence of eosinophil derived neurotoxin and non-secretory ribonuclease. The monoclonal
antibodies 2C2 and 6D3 only bind beta core-fragment (peptide 2) whilst the polyclonal (rabbit) antibody
AK12 could bind all three peptides. The radioimmunoassay system using AK12 could be inhibited by all three
peptides and the immunoradiometric assay although based on a capture antibody (2C2) that only bound
peptide 2, had the potential to measure all three peptides (when bound together as UGP) at the second step
when '25l-AK12 was introduced as the detector. A specific radioimmunoassay for peptide 3 was generated
using 1251-peptide 3 and the AK12 antibody. Beta core-fragment on iso-electric focusing was found to have a
pl >9.5, peptide 3 showed two bands at pl = 3.5 and 3.8 whilst insufficient purified peptide 1 was available to
determine its iso-electric point. Bioassay studies on UGP showed that any biological activity could be
attributed to trace contamination with hCG.
Urinary gonadotrophin peptide (UGP) has been purified
from the urine of patients with trophoblastic and non-
trophoblastic disease (Kardana et al., 1988). It has also been
detected in 93% (77/83) of tumours examined immunohis-
tochemically (Kardana et al., 1988). The apparent molecular
weight is 15,000. UGP cross reacts with antisera to hCG
beta-core fragment, which contains at least one epitope in
common with the beta-subunit ofhCG, as seen by the ability
to measure beta-core fragment using antisera raised to hCG
beta-subunit (Cole et al., 1988; Papapetrou & Nicopoulou,
1986; Wehmann & Nisula, 1980). Initial screening of urines
using specific immunoassays for UGP (Kardana et al., 1989)
has shown detectable levels of UGP in normal subjects and
elevated levels in the urine of some patients with neoplasms
(manuscript submitted for publication).
The origin of beta-core fragment (BCF) is unclear and
there are reports that it is a renal breakdown product of
either hCG or its beta-subunit (Akar et al., 1988; Blithe et
al., 1988). It has been shown that the major form of beta-
core fragment in serum exists as a high molecular weight
complex (Mr >60,000) which can be dissociated with 3M
ammonium thiocyanate to release beta-core fragment (Mr=
15,000) (Kardana & Cole, 1990).
In this paper we report further characterisation of UGP
using high pressure liquid chromatography, amino acid se-
quencing and iso electric focusing. Purified UGP and its
components were also used to determine immunoassay spec-
ificity and bioassay activity.
Materials and methods
Purification of UGP
A commercial preparation of hCG (Pregnyl) derived from
pooled pregnancy urines was subjected to gel filtration on
Sephadex G 100 and immunoadsorption with a mouse
monoclonal P-directed antibody (W14) immobilised on cyan-
ogen-bromide activated Sepharose 4B, the required material
being eluted with 3 M ammonium thiocyanate followed by
immediate desalting by G25 chromatography, according to
procedures published earlier (Kardana et al., 1988). Aliquots
of the immunoadsorbed material were further purified on
FPLC using a Superose 12 column (Pharmacia FPLC sys-
tems) or re-subjected to gel-filtration using Sephadex G-100.
As an alternative, UGP (determined by immunoassay) from
the first gel-filtration step, was loaded on to a Concanavalin
A-Sepharose column (Pharmacia Fine Chemicals) that was
equilibrated, then eluted with Con A buffer and finally eluted
with Con A buffer containing 0.5 M a-methyl-D-mannoside.
The bound material was dialysed against 0.05 M ammonium
bicarbonate, then loaded onto a DEAE-Sephacel column,
washed with 0.05 M ammonium bicarbonate and eluted with
a 0.05-0.5 M ammonium bicarbonate gradient. The unbound
fraction from DEAE chromatography was immunoadsorbed
as above and desalted using Sephadex G 100 (2.5 x 80 cm
column). The unbound material from Con A chromatog-
raphy was also immunoadsorbed and desalted on Sephadex
G 100.
UGP from normal male urine or ovarian carcinoma urine
was extracted using acetone precipitation (as described in
Kardana et al., 1988), whilst urine from a patient with
hydatidiform mole was extracted using either acetone preci-
pitation (as above) or as an alternative kaolin adsorption was
used. Two litres of urine were adjusted to pH=4.5 with
glacial acetic acid and then 35 g of kaolin (a modification of
the method of Albert, 1956, that does not include the final
precipitation step) stirred into this solution. The kaolin cake
was resuspended several times and then left overnight to
settle. The clear supernatant was discarded and the kaolin
cake filtered and washed with 2.5 litres of distilled water
containing 2.5 ml glacial acetic acid. The kaolin cake was
desorbed using 500 ml of 2 M ammonium hydroxide and the
pH of the filtrate adjusted to pH = 7.5 with glacial acetic
acid. The mixture was then concentrated to 5 ml using ultra-
filtration (YM-5 membrane, Amicon, Stonehouse, Gloucs.,
UK). The purification procedure then followed the route
already published: gel-filtration, antibody purification fol-
lowed by immediate desalting on a Sephadex G-25 column.
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High Pressure Liquid Chromatography (HPLC)
Purified UGP (as above) was subjected to reverse phase
HPLC using a Brownlee Aquapore 'RP-300' C-8, reverse
phase column, 60 x 2.1 mm, and a solvent programme con-
sisting of a 30 min, linear gradient of 10-65% acetonitrile in
water with 0.05% trifluoroacetic acid in both solvents. The
flow rate was 0.2 ml min-'. Absorption was measured at
214 nm and the amount of material present was estimated
from the peak areas and flow rate using the approximation
that a 0.1 mgml-1 solution of protein has A214 of 1.
Fractions from HPLC were collected and subjected to
N-terminal amino acid sequence analysis by automated Ed-
man degradation using an Applied Biosystems (Warrington,
UK) 470A gas phase sequencer. Amino acids were detected
as their phenylthiohydantoin (PTH) derivatives using an
Applied Biosystems 12A HPLC calibrated with standard
PTH-amino acids. Sequence homology with known peptides
was analysed using the Beckman Micro-Genie software
(Beckman, High Wycombe, Bucks, UK).
In vitro bioassay
A modification of a bioassay using mouse Leydig cells (Van
Damme et al., 1974) was used to measure the potency of
UGP prior to HPLC purification and of the fractions
obtained after HPLC separation. Decapsulated testes from
C.B.A. x Balb C strain mice were mechanically disrupted
and the cell suspension washed with DMEM (Flow Labora-
tories, Rickmansworth, UK) containing 2% foetal calf ser-
um.
One hundred Id of cell suspension was incubated with
100 ly of either UGP or its disassociated peptides (derived
from pregnancy urine), in DMEM for 2 h at 35°C in an
atmosphere of 95% oxygen and 5% carbon dioxide. The
samples were then centrifuged at 600g for 10min and the
supernatant decanted. The testosterone levels secreted into
the medium were measured using a radioimmunoassay
system purchased from Amersham (Amersham International
PLC, Amersham, UK). Counting was achieved using a scin-
tillation counter.
Immunoassays
UGP and the fractions obtained from HPLC chromatog-
raphy, were measured for immunological activity using both
radioimmunoassay (RIA) and immunoradiometric assay
(IRMA) in the systems previously described (Kardana et al.,
1989). A radioimmunoassay for peptide 3 was generated
using the AK12 antibody system with 251I-peptide 3 instead
of 251I-UGP. Specificity was determined by the addition of
UGP, hCG, P-subunit and beta-core fragment standards.
Antibody binding data
The binding specificities of the different antibodies were com-
pared using different radio iodinated ligands. Five pg of each
ligand was iodinated with 1 mCi 1251 (Amersham) using the
iodogen method (Fraker & Speck, 1978). Specificity activities
were in the range 100-150 iCi/iLg. Fifty iLl antibody, 50 l
iodinated ligand and 100jil phosphate buffer (0.05 M pH =
7.5) containing 0.1% (w/v) bovine serum albumin were incu-
bated overnight at room temperature, then precipitated with
501tl goat anti-rabbit or rabbit anti-mouse anti-species anti-
sera (prepared at Charing Cross Hospital by multiple mon-
thly subcutaneous injections of IgG fractions) and 1001 l of
5% polyethylene glycol 6000 for 2 h at room temperature.
The precipitated radioactivity was measured using a gamma
counter. Polyclonal antibody dilutions used in the binding
data were the same as those used in the radioimmunoassays.
Isoelectricfocusing
One lag of the protein to be focused was applied to the IEF
gel (Pharmacia Phast System) with an isoelectric focusing
range of 3-9, together with appropriate pl standards. After
focusing, the gels were developed using silver staining.
Purified peptide 2 (beta-core fragment) and peptide 3 were
obtained after reverse phase HPLC and confirmed pure by
sequence analysis.
Chromatography ofnormal male urine
Three ml of normal male urine was chromatographed on a
column of Sephadex G-100 (2.5 x 85 cm). Fractions were
measured for peptide 3, by immunoassay.
The G-100 columns had been calibrated previously with
the following molecular weight markers: yeast alcohol dehy-
drogenase (150,000 D); bovine serum albumen (66,000 D);
carbonic anhydrase (29,000 D); cytochrome C (12,400 D);
aprotinin (6,500 D). (Kardana et al., 1988).
Results
High pressure liquid chromatography and amino acid
sequencing
Pregnancy UGP purified by gel-filtration, antibody affinity
chromatography then rechromatographed on a Superose 12
column, as well as purified UGP from the three other sources
was subjected to HPLC separation (Figure 1). In each case,
three fractions (1, 2 and 3) were consistently observed in the
traces through proportions varied from different sources. All
fractions were subjected to amino acid sequencing. Amino
acid sequence data was obtained for fractions 1, 2 and 3.
Minor late fractions from HPLC separation were submitted
for amino acid analyses, but no amino acid sequences could
be assigned and those low molecular weight contaminants
were not further investigated. The sequence of fraction 2 was
completely homologous with that of beta-core fragment
(Birken et al., 1988) which corresponds with residues 6-40
disulphide linked to residues 55-92 on the beta-subunit of
hCG (Bahl et al., 1972). N-terminal amino acid analysis of
fraction 2 indicated the presence of two peptide chains, in
approximately equimolar proportions. Data was obtained for
the first 28 amino acid pairs. Cysteine residues were not
identified during analysis but the apparent lack of a residue
at those positions where cysteine is known to be present in
P-core-fragment is consistent with the presence of cysteine. In
addition, a low yield of aspartate (as its PTH derivative) was
obtained at position 8. This residue has been identified as
glycosylated asparagine in P-core-fragment and the detection
of low levels of aspartate is consistent with this assignment.
As far aw we were able to determine there was no sequence
homology with fraction 1 and any other known protein, but
sequence analysis shows it to be a peptide consisting of at
least 19 amino acids. Fraction 3 appeared as a doublet on
reverse phase chromatography with Rr 13-14 min. This frac-
tion consisted of at least 18 amino acids which were homo-
logous with the N-terminal sequence of eosinophil derived
neurotoxin and non-secretory ribonuclease (Beintema et al.,
1988). (Table I). Although broad peaks were sometimes
Footnote
The carbohydrate structures of hCG and its subunits result in appar-
ent molecular weights in gel chromatography which are not in direct
accord with those which would be assigned based on primary struc-
ture and sequence data: hCG with a molecular weight of around
38 kD is eluted from G100 at an apparent molecular weight of
70 kD, free P-subunit elutes apparently at about 60 kD, a-subunit
apparently 25-30 kD. The peak at an apparent molecular weight of
15 kD which contains material immunoreactive with P-directed anti-
sera and P-core fragment directed antisera can comprise overlapping
molecules whose elution will be affected by charge and carbohydrate
composition, in particular P-core fragment of hCG with or without
associated peptides. The further resolution on reverse phase HPLC is
needed to elucidate these components. Gel electrophoresis of our
preparations (Phast-gel or Micrograd) yielded a predominant well-
defined band at 15 kD in non-reducing conditions (data not shown).688 A. KARDANA et al.
UGP-
Peptide 1
0.311 I
0.1 -
0-
0.3 -
0.2
E
' 0.1-
4 0
j 0.3j
a)
X 0.2- Q0
0 n
0.1-
0.-
0.5-
0.4
0.3
0.2-
0.1
O-
0
UGP-
Peptide 2 UGP-
I, I Peptide3
a
C
Table I N-terminal amino acid sequences of the constituents of
UGP. The peptide 2 sequence is homologous with that of beta-core
fragment and corresponds to residues 6-40 (2a) disulphide linked
with residues 55-92 (2b) of hCG-beta subunit. Peptide 1 shows no
significant sequence homology with known proteins. Peptide 3 has
the N-terminal sequence of non-secretory ribonuclease and
eosinophil derived neurotoxin
Peptide 1
1 10
Asp Val Lys (-) Asp Met Glu Val Ser Ser Pro Asp
14
Gly Tyr Thr Ser (-) Arg Leu . . .
Peptide 2
6 10
(a) Arg Pro Arg (-) Arg Pro lie Asp Ala Thr Leu Ala
55 60
(b) Val Val (-) Asn Tyr Arg Asp Val Arg Phe Glu
Ser
20 28
(a) Val Glu Lys Glu Gly (-) Pro Val (-) Ile Thr . . .
70
(b) Ile Arg Leu Pro Gly (-) Pro Arg Gly Val Asn Pro
80
Val Val Ser Tyr . . .
Peptide 3
1 10
Lys Pro Pro Gln Phe Thr (-) Ala Gln (-) Phe Glu
15
Thr Gln (-) Ile (-) Met
(-) No amino acid was detected above background: these positions
correspond with cysteine residues of hCG-P subunit, as determined
by Bahl.
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Figure 1 Reverse phase high pressure liquid chromatograms of
UGP from a, urine from a normal adult male b, urine pool from
a normal pregnancy c, urine from a patient with hydatidiform
mole, post evacuation and d, urine from a patient with ovarian
carcinoma. In each case at least three distinct fractions are pres-
ent.
obtained for fraction 2, the amino acid sequence of samples
taken over this peak showed the same N-terminal amino acid
sequences. The sequence analysis showing molar yields after
each cycle is shown in Table II.
The association of peptide 3 with 2 was also confirmed
using immunoassay as well as amino acid sequencing, in the
pregnancy material that bound to Con A (contains most of
the beta-core fragment activity), the unbound fraction from
the DEAE chromatography (contains most of the beta-core
fragment reactivity) and finally after gel-filtration ofantibody
purified material. Fractions obtained by gradient elution of
DEAE had only baseline levels of peptide 2 and 3 by
immunoassay. The unbound fraction from Con A also con-
tained peptides 2 and 3 (as demonstrated by immunoassay
and sequencing) which also were still associated after anti-
body purification (using immobilised PCF specific antibodies),
followed by gel-filtration. However, this product contained at
least 10 fold more peptide 3 than peptide 2, which would
suggest more than non-specific binding of peptide 3 to the
antibody column, especially as we have shown that peptides
1 and 3 do not bind PCF antibodies. The association of
peptide 1 was more difficult to follow as this appears to be
present at lower levels making sequencing more difficult and
a specific immunoassay was not available.
The sequence of peptides 1, 2 and 3 were confirmed using
purified material from pregnant females and from a patient
with a hydatidiform mole. The sequence of peptides 1 and 3
were also confirmed using purified material from a normal
male and peptide 1 from a patient with ovarian carcinoma.
The presence ofpeptide 2 in the UGP from the normal male
and the ovarian carcinoma patient was confirmed by beta-
core fragment immunoassay. The presence of peptides 1, 2
and 3 in material extracted by kaolin adsorption instead of
acetone precipitation, was also confirmed using amino acid
sequencing. The immunoassays and sequence analyses were
tools used to identify the structures present after different
purification steps and by themselves do not confirm associa-
tion. Association is inferred by the continuous presence of
the peptides after different purification steps.
Immunoassays
UGP and peptide 2 showed immunological activity in both
the RIA and IRMA systems, whilst purified peptides 1 and 3
only showed immunological activity in the RIA system (Fig-
ure 2), the reactions of 1 and 3 being linear with concentra-
tion and parallel to the UGP response. In the IRMA system,
positive response by the peptides 1 and 3 is numerically small
and non-parallel and can be discounted in measuring peptide
2. The RIA generated for peptide 3 had a working range of
400-8 ngml-', 10% cross-reactivity with UGP, 0% cross-
reactivity with hCG and P-subunit at 1 gg ml1' and 0%
cross-reactivity with beta-core fragment at 2jigml-'.
In vitro bioassay
UGP and dissociated UGP peptides were tested for bioac-
tivity in the range 1-100 ngml'. HCG in the range
3-400 pgml1' was the control. Some bioactivity was seen at
the higher concentrations of UGP which can be attributed to
contamination by intact hCG (0.2% by immunoassay). Until
this potential contamination can be eliminated comparative
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Figure 2 a, UGP inhibition studies using the AK12 antibody
with 25I-UGP (RIA system). b, UGP binding studies using 2C2/
'251-AK12 (IRMA system). 0--- O Intact UGP; 0--- 0
UGP-peptide 1; A-- -A UGP-peptide 2; x -----x UGP-
peptide 3. The RIA system shows inhibition by UGP and all
three peptides whilst the IRMA system shows binding with UGP
and core-fragment.
studies of biological activity between the peptides will be
compromised.
Antibody binding data
The monoclonal antibodies 2C2 and 6D3 only bind UGP or
peptide 2 of UGP. This is also the case for antibodies W14
and DR-Pool although they show additional binding to hCG
and its beta-subunit. The only antibody preparation which
showed any binding with peptides 1 and 3 as well as peptide
2 was the AK12 polyclonal (rabbit) antiserum. Further
details on epitope specificities have been published earlier
(Kardana et al., 1988, Kardana, 1990; Searle et al., 1984).
Isoelectricfocusing
Purified peptide 3 focused characteristically as two bands at
pI = 3.5 and pI = 3.8. Peptide 2 migrated towards pl = 9.0 if
the gel was visualised before focusing was complete. When
focusing had reached completion the peptide 2 band was
often lost off the top of the gel, indicating a pl greater than
the range of the gel. Insufficient purified peptide 1 was
available to visualise on gels.
Urine chromatography
Fractions from the gel-filtration of normal male urine when
analysed for peptide 3 by immunoassay, demonstrated only
one region of immunoreactivity. This was at Mr = 15,000,
the same as that for UGP. There was no additional peak of
immunoreactivity for peptide 3 in the lower molecular weight
region.
Discussion
HPLC separation of purified preparations of UGP from
different source material showed at least three distinct peaks
in each case. The amino acid sequence of peptide 1 did not
identify it as a previously known sequence. Peptide 2 was
identified as the beta core-fragment of hCG, and peptide 3
appears to be related to non-secretory ribonuclease U (RN-
ase U) but the final structure remains to be elucidated.
Initially, reverse phase HPLC was used as a final 'clean-up'
of the beta-core fragment preparations and the additional
peptides (1 and 3) were regarded as contaminants. However,
successive UGP purifications, from the urine of patients with
different malignancies, also showed the presence of the same
two peptides. It was felt therefore, this warranted further
investigation.
The association of peptide 3 with beta core-fragment, in
UGP purified from pregnancy material, was confirmed by
immunoassay and sequencing, at each step, after gel-filtration
followed by Con-A purification followed by ion-exchange
chromatography followed by purification using immobilised
antibodies and finally gel-filtration (Sephadex G-100) again.
The association of peptide 1 with 2 and 3 was confirmed by
sequencing at the final step, after gel-filtration, antibody
affinity purification and gel-filtration using Sephadex G-25.
Dissociation of peptides 1, 2 and 3 was obtained under the
denaturing conditions of reverse phase HPLC.
In order to eliminate the possibility that the association of
these peptides occurred as a result of the initial acetone
precipitation step in the extraction procedure (Kardana et al.,
1988), an alternative concentration step was used which
relied on adsorption to kaolin. However, although the UGP
recovery was not as good using the kaolin method (only
about 25% of the acetone precipitation recovery), all three
peptides were again detected. These data are strong indica-
tors of association, although they do not conclusively elim-
inate the possibility of co-purification.
When normal male urine was chromatographed and ana-
lysed for peptide 3 by immunoassay, only one peak of
immuno-reactivity was obtained, which was in the region of
UGP (Mr = 15,000). If the association of beta-core fragment
with peptide 3 occurred at the kidney level, some unas-
sociated peptide 3 might be expected, as the beta-core frag-
ment content of normal urine is low (Nam et al., 1990).
The cervical carcinoma cell lines DOT and Caski were
reported as secreting a molecule with beta immunoreactivity,
that was larger than beta subunit, had the C-terminal peptide
missing and did not react with antibodies raised to the alpha
subunit of hCG (Hussa et al., 1986). It has been shown that
the major form of beta-core fragment in pregnancy serum
exists as a large molecular weight complex (Mr >60,000)
(Kardana & Cole, 1990). This complex, which does not
appear to be the result of non-specific binding of beta-core
fragment to serum proteins, can be dissociated with 3 M
ammonium thiocyanate. The identity of the associated mac-
romolecules is as yet unknown, but they are not hCG related.
UGP could possibly be the large molecules secreted by the
Dot and Caski cell lines, or the degradatory product of
serum beta-core fragment complex after processing by either
the liver or kidneys, and variable extent ofdegradation could
lead to variable stoichiometry.
Isoelectric focusing of peptide 2 (BCF) gives it a pl >9.0.
The high pl value observed would be consistent with a P-core
fragment lacking sialic acid, of the type fully investigated by
previous workers (Blithe et al., 1989) in that within hCG and
in X 1
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its subunits desialylated molecules have a higher pI than their
fully sialylated counterparts. It has been shown that the
glomerular basement membrane (GBM) of the kidney has a
large distribution of anionic sites (Brenner et al., 1977;
Caulfield & Farquhar, 1976; Chang et al., 1975). These
anionic sites are due to sialo-glycoproteins present within the
GBM which repel anions, thus hindering their passage
through the GBM into the urinary filtrate and keeping them
in the plasma circulation. It has also been shown that strong
cations with pl >8.8 are rapidly cleared from the circulation
and have been demonstrated within the basement membrane,
but they cannot be detected in the urinary spaces (Rennke et
al., 1975; Venkatachalam & Rennke, 1978). These are
thought to be taken up and processed in lysosomes. There-
fore beta-core fragment with a pI >9.0 would also not be
expected to be found in the urinary filtrate, except maybe at
low levels. It has been reported (Lefort et al., 1986) that hCG
and hCG beta-subunit, when infused into rats appears as
intact hCG or beta-subunit in serum, which is catabolised
and appears as a fragment that has anti-beta immunoreac-
tivity but no anti-CTP immunoreactivity in liver and kidney
homogenates, whilst in the urine a small molecular form
which has only immunoreactivity with the CTP antibodies
was detected. In addition, the beta immunoreactive form that
was detected in the kidney homogenates, appeared after
30 min of infusion with hCG, but the amount of this frag-
ment in the kidney, remained fairly constant even after 6 h.
Virtually no beta-immunoreactive fragment was detected in
the rat urine. This data supports the above statement that if
beta-core fragment was circulating unassociated, it would be
removed and retained by the kidney GBM and would not
filter into the urine.
However beta-core fragment is detected at high levels in
pregnancy and trophoblastic urine (Blithe et al., 1988; Kato
& Braunstein, 1988; Papapetrou & Nicopoulou, 1986). Sim-
ilarly, peptide 3 with its strong anionic charge should be
repelled from the GBM and thus the urinary filtrate. Perhaps
the association of peptides 1, 2 and 3 as UGP, modifies the
overall charge of the molecule and thus enables UGP to pass
through the GBM into the urine.
Further work needs to be done to determine where UGP
association occurs and if there is any link with the serum
beta-core fragment complex or the larger molecules detected
in cervical carcinoma culture medium. Perhaps the additional
peptides in UGP could be used as a starting point to try and
identify the associated macromolecules in the serum beta-
core fragment complex.
In conclusion, the association of peptides 1, 2 and 3 as
demonstrated by the techniques we have used, appear to be
specific. However, whether the association is specific or a
co-elution problem, this report should alert other inves-
tigators purifying beta-core fragment, using these standard
biochemical methodologies.
The two immunoassays (RIA and IRMA) used to monitor
UGP have different characteristics. The AK12 RIA has
antibodies to peptides 1, 2 and 3 so when all three peptides
are iodinated (as UGP) this system can measure UGP and
any free peptides, if they occur. However when only peptide
three was iodinated, a specific assay for peptide 3 resulted
that did not cross-react with peptides 1 and 2.
The 2C2 IRMA used a capture antibody specific for beta-
core fragment (peptide 2) and radioiodinated AK12 as tracer.
These measurements could be regarded as values of UGP, or
amplified beta-core fragment, as additional tracer could bind
to peptides 1 and 3 when they are associated with beta-core
fragment as UGP.
An analysis of the results obtained on urine samples from
patients with trophoblastic and non-trophoblastic neoplasms,
using these immunoassays, will be used to assess the value of
UGP, as opposed to beta-core fragment, as a tumour
marker.
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